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ABSTRACT 
Introduction: Social determinants of health play an important role in explaining poor 
health outcomes across many chronic disease states. The impact of the social gradient in 
the setting of an inherited heart disease, hypertrophic cardiomyopathy (HCM), has not 
been investigated. This study sought to profile the socioeconomic status of patients 
attending a specialized multidisciplinary clinic and to determine the impact on clinical 
factors, psychosocial wellbeing and adherence to medical advice.  
Methods: Patients with HCM and at-risk relatives attending a specialized multidisciplinary 
clinic in Sydney Australia between 2011-2013 were included. Clinical, socioeconomic, 
geographic remoteness and adherence data were available. A broader clinic and registry-
based group completed a survey including psychological wellbeing, health-related quality 
of life, Morisky Medication Adherence Scale and individual-level socioeconomic 
information.  
Results: Over a 3-year period, 486 patients were seen in the specialized clinic. There was 
an over-representation of patients from socioeconomically advantaged and the least 
geographically remote areas. Socioeconomic disadvantage was associated with 
comorbidities, poor psychological wellbeing and health-related quality of life, lower 
understanding of HCM and more complex clinical management issues such as NYHA 
class, atrial fibrillation and left ventricular outflow tract obstruction. Approximately 10% of 
patients were non-adherent to medical advice, and poor medication adherence was seen 
in 30% of HCM patients with associated factors being younger age, minority ethnicity, 
anxiety and poor mental quality of life.  
Conclusions: Of patients attending a specialized cardiac genetic clinic, there is an 
overrepresentation of patients from very advantaged and major metropolitan areas and 
suggests those most in need of a multidisciplinary approach to care are not accessing it. 
 
Keywords: Hypertrophic cardiomyopathy, social determinants of health, adherence  
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INTRODUCTION 
A universal healthcare system endeavors to provide equitable access to all avenues of 
health care and services for the population. In reality, social determinants, including social 
and economic circumstances, affect health throughout life. The World Health Organization 
(WHO) defines social determinants of health as the conditions into which people are born, 
live, work and age [1]. These include socioeconomic characteristics, which are potent 
determinants of health. Individuals further down the socioeconomic ladder have an 
increased risk of serious illness and premature mortality relative to those of higher status, 
and these effects are not restricted to the most disadvantaged, but rather operate as a 
social gradient across society [2]. Socioeconomic factors also influence how individuals 
interact with health care services. For example, low socioeconomic status has been 
consistently associated with lower utilization of general and preventive health checks [3], 
lower uptake of disease-specific screening programs such as breast cancer screening [4] 
and poorer access to disease-specific health care services such as cardiac services [5]. 
These social gradients in the use of health services may contribute to social inequities in 
health outcomes, and hence are important considerations in optimizing health care and 
services.  
 
To date, no study has investigated the importance of socioeconomic characteristics as 
determinants of health service use or clinical outcomes in the setting of a genetic heart 
condition such as hypertrophic cardiomyopathy (HCM). HCM is the most common genetic 
heart condition, affecting at least 1 in 500 of the general population and is characterized by 
left ventricular hypertrophy in the absence of other loading conditions [6]. There is 
significant variability in the clinical presentation and natural history of disease, but 
undoubtedly the most tragic outcome is sudden cardiac death (SCD) [7]. Being a genetic 
condition, first-degree (at-risk) relatives are advised to undergo lifetime clinical surveillance 
due to a 1 in 2 risk of inheriting the gene mutation. HCM is an autosomal dominant genetic 
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disease, and despite rare founder mutations [8] affects the population equally. Disease 
guidelines exist, and while some controversies remain, the diagnosis, medical 
management and clinical/genetic surveillance of the family is established [9]. In Australia 
and worldwide, the multidisciplinary specialized cardiac genetic clinic is advocated as the 
ideal model of care for HCM families, offering expertise from genetic counselors, 
cardiologists, and others (Figure 1). The cost-effectiveness of a specialized 
multidisciplinary service incorporating genetic testing has recently been shown both in an 
Australian [10] and British [11] health care system highlighting the significant benefit of this 
type of service.  
 
Little is known about the sociodemographic profile of patients attending a multidisciplinary 
cardiac genetic clinic. This study sought to profile the socioeconomic and geographic 
characteristics of consecutive patients attending a specialized clinic over a 3-year period, 
and in a broader patient population to identify whether social determinants such as 
education, income and geographic remoteness, impact on clinical factors, psychosocial 
wellbeing and adherence to medical advice.   
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METHODS 
Consecutive clinic patient group 
Consecutive patients attending a specialized cardiac genetic clinic in Sydney Australia, 
over a 3-year period from January 2011 through December 2013 were included in this 
study. Patients with a diagnosis of HCM, those investigated for possible HCM and all first-
degree at-risk relatives who attended during the time period were included. Patients who 
failed to attend their appointment, but for whom enough clinical information could be 
gathered from the referral letter were included. Information available for this patient group 
included clinical data (i.e. disease status, clinical history, echocardiographic data, family 
history and genetic status), postcode, adherence and referring doctor’s details.  
 
Patient adherence to guidelines 
Adherence to medical advice and current guidelines was determined. For those with HCM, 
individuals were assessed based on their regularity of attendance for cardiology review, 
with those not being seen on at least a 2-yearly basis classified as non-adherent. Patients 
who declined to take a medication prescribed to them, who continued to participate in 
high-level or competitive sports, and who declined ICD therapy against recommendations 
were also considered non-adherent. Non-adherence was adjudicated by the 
multidisciplinary team and based on clinic encounters within the study period. At-risk 
relatives were considered non-adherent if they failed to attend for clinical screening as per 
the guidelines despite knowledge of this recommendation. 
 
Socioeconomic status and geographic remoteness 
Socioeconomic status was assessed using an area-level approach to categorize 
participant’s neighbourhood of residence using the Index of Relative Socioeconomic 
Advantage and Disadvantage (IRSAD) and the Index of Education and Occupation (IEO). 
Geographic remoteness of participant’s place of residence was determined by a 
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Remoteness Areas (RA) classification, developed by the Australian Bureau of Statistics 
and based on postcode. 
 
The IRSAD is one of the Socioeconomic Indexes for Areas (SEIFA) 2011 developed by 
the Australian Bureau of Statistics [12], and ranks every region of Australia by relative 
socioeconomic advantage and disadvantage based on data collected in the 5-yearly 
Census. Decile 10 is the most advantaged and least disadvantaged area. The IEO was 
also developed as part of the SEIFA 2011, and is an index based around the skills of the 
people in an area, including both formal qualifications and skills required for different 
occupations. For this study, both indexes were grouped by top and bottom 50% of deciles 
to create a binary variable. The base unit of postal area code was used. 
 
Geographic remoteness was determined by the ABS Australian Standard Geographical 
Classification (ASGC) Remoteness Areas classification, which correlates with the 
categories of the previously used Accessibility/Remoteness Index of Australia (ARIA+) 
[13]. Areas are defined by the distance a person must travel along a road network to reach 
goods, services and opportunities for social interaction. Remoteness area classifications 
include RA1, “Major cities of Australia”; RA2, “Inner regional”; RA3, “Outer regional”; RA4, 
“Remote” and RA5, “Extremely remote”.  
  
Psychosocial survey patient group 
A broader patient group was approached to complete a detailed psychosocial survey 
(Figure 2). This included all patients with a diagnosis of HCM and first-degree relatives 
who had previously attended the specialized cardiac genetic clinic, or those who were 
enrolled in the Australian Genetic Heart Disease Registry [14] (enrolled from the Sydney 
site or not associated with any major recruiting sites, i.e. self-enrolled participants). 
Participants were aged 18 years and above and were required to have sufficient English 
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skills to complete the survey. Participants were approached either in person while 
attending the specialized clinic, by phone call, post or by email between 2012 and 2014.  
 
The survey comprised the Medical Outcomes Short-Form 36 version 2 (SF36v2) [15], 
Hospital Anxiety and Depression Scale (HADS) [16], HCM Patient Experience Scale,[17] 
Understanding and Satisfaction with Understanding Scale,[17] Morisky Medication 
Adherence Scale (MMAS-8) [18] and sociodemographic questions (further information in 
supplementary material). 
 
Socioeconomic status was determined using the area-level measures, IRSAD and IEO, 
and in addition was based on individual-level data including self-reported highest 
education level and household income (selected from predefined categories), two 
commonly used proxies for socioeconomic status [19]. For education, a binary variable 
was created to identify individuals who had attained a university level qualification (high 
education) and those who had not (low education). Similarly, for income, responses were 
converted to a binary variable where those who indicated their household income was 
$AUD1300 ($US1220, €910) per week and below considered low income (based on 
approximate Australian median household income) [20].  
 
Statistical analysis 
Data were analysed using SPSS version 22.0 software. Descriptive statistics were used to 
examine the socioeconomic and geographic profile of clinic patients. Associations 
between socioeconomic and geographic indicators and continuous and categorical 
outcome variables were analysed using student’s t-test and chi-squared analysis, 
respectively. Factors associated with medication adherence were assessed using bivariate 
logistic regression models allowing for adjustment by patient age, given the high likelihood 
of confounding.    
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RESULTS 
Characteristics of the consecutive clinic patient group 
Over a 3-year period from January 2011 to December 2013, 486 individuals meeting the 
inclusion criteria were seen in the specialized cardiac genetic clinic (Table 1). This 
included 342 (70%) individuals with HCM and 144 (30%) at-risk relatives. For those with 
disease, the mean age was 46 ± 17 years and 212 (62%) were males. Mean age at 
diagnosis was 39 ± 19 years and 147 (54%) presented symptomatically. There were 98 
(35%) with an ICD, 142 (53%) with a family history of HCM including 45 (16%) with a 
relative dying suddenly. The mean maximum left ventricular (LV) wall thickness was 21 ± 6 
mm and 32 (12%) had severe hypertrophy of 30mm or more. In addition, 67 (25%) had 
evidence of LV outflow tract obstruction at rest, 46 (17%) had atrial fibrillation, 101 (44%) 
had NYHA functional class of II-IV, and 16 (6%) had a previous SCD event (including 
resuscitated cardiac arrest, appropriate ICD therapy or SCD). At-risk relatives had a mean 
age of 29 ± 16 years and 69 (48%) were males.  
 
Characteristics of the referring doctor for patients seen in the specialized clinic 
There were 137 (41%) new patients seen over the study time period, and the remainder 
included those who were regularly followed up in the specialized clinics. In most cases, 
new patients had an existing diagnosis and this was their first presentation at a specialized 
clinic. Overall, 211 (64%) HCM patients were referred to the clinic by a specialist, which 
included adult and pediatric cardiologists, cardiac electrophysiologists and clinical 
geneticists. Of new patients seen in the clinic over the study period, 121 (88%) were 
referred by a specialist, compared to 90 (46%) specialist referrals for follow-up patients 
(p<0.0001). Only 16 (11%) at-risk relatives had a specialist referral to the clinic (p<0.0001) 
and 69 (49%) were seen as new patients during the study period.   
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Adherence to guidelines amongst clinic patients 
Adherence to clinical guidelines was investigated across the consecutive clinic group, with 
35 (10%) HCM patients and 10 (7%) at-risk relatives identified as non-adherent. Of those 
with HCM, 12 of 112 (10%) patients with clear risk factors for SCD declined ICD therapy 
despite medical advice. There were 13 (4%) HCM patients who did not see their 
cardiologist on a regular basis, 2 (0.6%) who continued to play high-level competitive 
sports and 8 (2%) who declined to take a prescribed medication, including beta-blockers, 
other anti-arrhythmics and anticoagulants.  
 
Socioeconomic and geographic profile of patients attending the specialized clinic 
The socioeconomic and geographic profile of clinic patients is summarized in Figure 3. Of 
the consecutive patient group, there were 241 (71%) HCM patients residing in the most 
advantaged 50% of IRSAD deciles (i.e. top 50% most advantaged areas) and 89 (26%) 
from the top most advantaged decile (decile 10; i.e. top 10% most advantaged areas). 
There were 105 (73%) at-risk relatives from the most advantaged 50% of IRSAD deciles 
and 27 (35%) from the top most advantaged IRSAD decile. There were 250 (76%) HCM 
patients residing in areas with an IEO in the top 50% of deciles (i.e. top 50% most 
educated areas) and 74 (22%) in the top most educated decile (decile 10; i.e. top 10% 
most educated areas). There were 106 (74%) at-risk relatives in the top 50% IEO deciles 
and 31 (22%) in the top decile.    
 
There were 403 (85%) clinic patients who resided in the least remote category, “RA1 – 
Major cities of Australia”, including 278 (84%) HCM patients and 125 (87%) at-risk 
relatives. There were 40 (12%) HCM patients and 12 (8%) at-risk relatives from category 
“RA2 – Inner Regional”; and 9 (3%) HCM patients and 6 (4%) at-risk relatives from “RA3 – 
Outer Regional”. Only 2 (0.6%) HCM patients and no at-risk relatives resided in “RA4 – 
Remote” region of Australia. No patients represented the most extreme remoteness 
! 10 
category “RA5 – extremely remote”. The proportion of the Australian population that reside 
in these remoteness areas is RA1 60.7%, RA2 24.6%, RA3 11.7%, RA4 2.0% and RA5 
1.0% (based on 1996 Australian Census data). 
 
Characteristics of the survey patient group 
The broader group approached to complete the survey included 610 patients from the 
Australian Genetic Heart Disease Registry and those seen in the specialized clinics from 
2002-2013, with 275 included in the final analysis (response rate 45%). This included 209 
(76%) patients with HCM and 66 (24%) at-risk relatives (Figure 2). 
 
Of the 209 HCM patients, 156 (78%) had previously been seen in the specialized clinic, 
while the remainder had self-enrolled in the Australian Genetic Heart Disease Registry or 
were family members of clinic patients (Supplementary Table). Mean age was 53 ± 15 
years and 120 (60%) were male. Clinically, the mean maximum LV wall thickness was 18 
± 8 mm, 37 (19%) had atrial fibrillation, 44 (23%) had LV outflow tract obstruction and 56 
(32%) reported NYHA functional class II-IV symptoms. Eighty-four (41%) patients had an 
ICD.  
 
Psychosocial and clinical factors associated with education level, household 
income and geographic remoteness in HCM patients 
Compared with HCM patients with a high household income, those patients with a low 
household income (Supplementary Table) were on average older (57 ± 16 versus 49 ± 13 
years, p<0.0001). Furthermore, HCM patients with a lower income were less likely to have 
been seen in the specialized clinic (71% versus 86%, p=0.01) and more likely to express a 
more complex disease phenotype including atrial fibrillation (24% versus 12%, p=0.03) 
and LV outflow tract obstruction (29% versus 17%, p=0.05). They were also more likely 
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than higher income patients to present with comorbidities (51% versus 33%, p=0.009). In 
terms of psychosocial differences, HCM patients with low income were more likely to be 
depressed (HADS-Depression scores ≥ 8, 28% versus 11%, p=0.004) and reported poorer 
physical quality of life (SF36v2 PCS, 44 ± 10 versus 47 ± 11, p=0.03). There was also a 
worse level of understanding of HCM in those with low incomes (14 ± 5 versus 16 ± 6, 
p=0.002).  
 
Compared with HCM patients with a higher education level, those with a lower level of 
education (Supplementary Table) reported a poorer understanding of HCM (14 ± 6 versus 
16 ± 6, p=0.03) and less satisfaction with their understanding (10 ± 3 versus 12 ± 3, 
p=0.001). They also had lower mental quality of life scores (SF36v2 MCS, 42 ± 17 versus 
47 ± 13, p=0.002) and less involvement in their medical management (11 ± 2 versus 12 ± 
2, p=0.01). In terms of symptoms, those from the lower educated group were more likely to 
have NYHA symptoms II-IV, though this only just reached statistical significance (41% 
versus 26%, p=0.05).  
 
Patients who resided in more remote areas of Australia (i.e. RA2 and RA3) were less likely 
to have been seen in the specialized clinic (60% versus 86%, p<0.0001), were less 
satisfied with their understanding of HCM (11 ± 3 versus 10 ± 3, p=0.04) and reported 
worse physical quality of life (SF36v2 PCS, 46 ± 11 versus 43 ± 10, p=0.05) 
(Supplementary Table).  The sub-domains of the SF36v2 were assessed (Figure 4) to 
provide further information about the quality of life impairments seen between the different 
socioeconomic groups.  
 
Medication non-adherence amongst HCM patients 
! 12 
Poor self-reported medication adherence was identified in 45 (30%) HCM patients who 
completed the survey. Factors associated with poor medication adherence compared to 
moderate-good adherence included age (52 ± 14 versus 59 ± 13 years, p=0.004), mental 
quality of life (SF36v2 MCS, 40 ± 17 versus 46 ± 14, p=0.03), non-white/Caucasian 
ethnicity (24% versus 8%, p=0.005) and HADS-Anxiety (44% versus 24%, p=0.01). After 
adjusting for age, non-white/Caucasian ethnicity remained significantly associated with 
poor medication adherence, despite wide confidence intervals (OR 3.43, 95%CI 1.24-9.52, 
p=0.018), while HADS-Anxiety showed only borderline significance (OR 2.12, 95% CI 
0.99-4.56, p=0.05) and mental quality of life remained significantly associated (SF36v2 
MCS, OR 0.98, 95% CI 0.95-0.99, p=0.045). None of the indicators of socioeconomic 
status or geographic remoteness were associated with poor medication adherence. 
 
Factors associated with clinical screening adherence amongst at-risk relatives 
Sixty-six at-risk relatives completed the survey, with a mean age of 47 ± 17 years and 22 
were males (33%). Of these, 17 were identified as being non-adherent to clinical screening 
advice (including 4 patients identified as non-adherent in the clinic patient group). Twenty-
three (35%) at-risk relatives had never been seen in the specialized clinic, but were 
recruited from the Australian Genetic Heart Disease Registry. There were 51 (77%) at-risk 
relatives residing in ‘RA1 – Major cities of Australia’, 12 (18%) in ‘RA2 – Inner regional’ 
and 3 (5%) in ‘RA3 – Outer regional’ areas. There was a statistically significant association 
between geographic location and non-adherence amongst at-risk relatives [RA1 (n=9, 
18%) and RA2/3 (n=8, 53%), p=0.015]. The self-reported level of understanding of HCM 
was found to be significantly worse in the non-adherent relatives compared to the 
adherent relatives (15.9 ± 5.5 versus 11.9 ± 5.5, p=0.014). No differences in IRSAD, IEO, 
psychological wellbeing and health-related quality of life were found between adherent and 
non-adherent relatives.   
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DISCUSSION 
Globally, health outcomes are socially determined, but to date no study has evaluated the 
impact of social determinants on health and clinical characteristics in the setting of genetic 
heart diseases such as HCM. The current study supports the notion that it is primarily the 
advantaged and well educated who comprise the greatest proportion of patients who 
attend a specialized HCM clinic. Lower socioeconomic groups were under-represented in 
the clinic setting. Further, those patients from lower socioeconomic groups were 
characterized by worse psychological wellbeing and health-related quality of life, lower 
understanding of HCM and had more complex disease presentations (including atrial 
fibrillation, LV outflow tract obstruction and NYHA class II-IV symptoms and comorbidities). 
Overall the study suggests that the patient groups with the most significant and complex 
health issues are those from a lower socioeconomic class, and that specialized 
multidisciplinary clinics that are advocated as an ideal model of care for HCM are not 
serving this patient group in an equitable way.  
 
Socioeconomic status, that is the individual’s social position relative to others, is known to 
be an important factor in the onset and progression of a number of health conditions 
including cardiovascular disease, with a low socioeconomic status associated with greater 
mortality and acting as a barrier to accessing high-quality health care [21, 22]. Inequities 
are considered avoidable disparities in delivery and access to health care and are driven 
by social, political and economic factors, and addressing these gaps is a major focus 
globally [22]. In Australia, whilst a universal health care system is in place, the provision of 
health care outside of hospitals is largely accessed via a combination of both private and 
public services, often resulting in a “user-pays” scenario [23]. A Medicare system exists, 
providing subsidies for most of the cost of doctor visits, incentives to provide bulk billing to 
concession card holders and a ‘Safety Net’ to cap out-of-pocket medical costs over a 
certain annual threshold [24]. However it is known that advantaged groups 
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disproportionally access and gain benefit from primary health care and specialist medical 
services, both in Australia [25] and elsewhere [26]. The confounding issue is that low 
socioeconomic status is frequently associated with a greater prevalence of chronic 
diseases and disease risk factors which taken together often give rise to more complex 
clinical management needs [27]. Our study highlights an overrepresentation of patients 
from very advantaged and major metropolitan areas, suggesting that the groups most in 
need of a multidisciplinary approach to care are not accessing it.  
 
The clinical profile of patients referred to and seen in a specialized clinic present more 
challenging management issues and often more complex patients. The HCM clinic in 
Sydney is a tertiary referral center, with 64% of the HCM patients referred by another 
specialist, including general cardiologists, pediatric cardiologists and cardiac 
electrophysiologists. Typically in this clinical setting, patients may be either (1) seen for a 
particular management issue then will continue their ongoing cardiac follow-up with their 
own cardiologist, or (2) choose to be followed-up in the clinic (Figure 1). Ideally, all HCM 
patients should be referred at least once to the specialized clinic where they can be 
reviewed by the cardiology team and engage with the genetic counselor to discuss familial 
aspects of disease and any genetic testing options available to them. More realistically 
however, the specialized clinic serves to support the most complex clinical and genetic 
management scenarios where expertize is critical to ensure the best outcomes for the 
patient. Based on what we understand about increased morbidity and mortality in more 
socioeconomically disadvantaged groups, there may be a greater need for 
multidisciplinary specialized clinic care in this population.  
 
Understanding the reasons for the disparity in the patient group accessing the specialized 
multidisciplinary clinic is challenging. Other groups have investigated inequities in access 
to specialist medical services and suggest it may be shaped by the health care system 
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itself, where despite a public system that can provide subsidies for many services, there 
still may be an out-of-pocket and/or private aspect [28]. Korda and colleagues suggest the 
reasons go beyond just cost, and shine a spotlight on the primary care physician/general 
practitioner as the gatekeeper for specialist referral [24]. Others suggest patient referral 
may be moderated by the perceived socioeconomic status of the patient, for example 
more disadvantaged patients may be expected to be non-compliant, and so the health 
practitioner does not make the referral [28]. In the setting of genetic heart disease 
management in a specialized clinic, it is unclear what the barriers are preventing referral of 
disadvantaged patients, though are likely a complex interaction of many different factors.  
 
The influence of socioeconomic status on patient adherence to medical advice and 
therapies has been previously described [3, 29]. Our study reports the overall prevalence 
of non-adherence in a consecutive patient series of 10%. In all cases after lengthy 
discussion it was ultimately the patient who decided whether they follow medical advice. In 
one instance, a young man with 3 well-established risk factors for SCD declined ICD 
therapy due to a belief that a change in his lifestyle to incorporate better diet and exercise 
would be protective. The patient still remains without an ICD despite his very high risk of 
an event. An analysis of socioeconomic factors that may explain non-adherent behaviour 
in this patient group found no association in the present study. Non-adherence is likely the 
result of a number of factors including experience with the disease (i.e. family history of 
SCD), symptomatic status and the various coping strategies people use to negotiate 
difficult situations. Further, poor medication adherence was reported in 30% of the 
surveyed patients who were taking a regular medication for their heart condition (n=150). 
Factors associated with poor medication adherence were younger age, non-
white/Caucasian ethnicity, anxiety and mental quality of life. Due to the high correlation 
between age and adherence, subsequent analysis adjusting for this was performed, and 
ethnicity, anxiety and mental quality of life remained significant suggesting greater 
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attention and a higher clinical suspicion of poor medication adherence for younger 
patients, those from minority ethnic groups and those indicating some anxiety or poor 
mental quality of life (e.g. lowered social functioning, lower perceived general health).  
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Conclusions 
The effect of socioeconomic status on clinic attendance, and on clinical and psychosocial 
outcomes is evident in the HCM patient population, and determining ways to better serve 
those from more disadvantaged groups who likely present more complex clinical 
management issues is critical. The underlying reasons for the disproportionate number of 
advantaged and highly educated individuals attending a specialized clinic are likely to be 
multifactorial. Further work to better understand these inequities is imperative if we are to 
provide equitable care to all HCM patients.   
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TABLE 1: Characteristics of consecutive patients seen in a specialized HCM clinic 
over a 3-year period 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Index for relative socioeconomic advantage and disadvantage (IRSAD), Index for Education 
and Occupation, high scores indicate those in top 50% of Australian population 
†Australian Statistical Geographic Standard (ASGS) 
‡Percentage calculated from the number of patients where an ICD was indicated 
Abbreviations; ICD, implantable cardioverter defibrillator; RA, remoteness area
 HCM patients At-risk relatives All patients 
N (%) 342 (70) 144 (30) 486 
Mean age, years (SD) 46 ± 17 29 ± 16 41 ± 18 
Male gender (%) 212 (62) 69 (48) 281 (58) 
White/Caucasian ethnicity 229 (67) 102 (71) 331 (68) 
Specialist referral 211 (64) 16 (11) 227 (48) 
Top 50% IRSAD areas* 241 (71) 105 (73) 346 (71) 
Top 50% IEO areas* 250 (76) 106 (74) 356 (73) 
Geographic remoteness†     
   Major Cities of Australia (RA1) 278 (84) 125 (87) 403 (85) 
   Inner regional (RA2) 40 (12) 12 (8) 52 (11) 
   Outer regional (RA3) 9 (3) 6 (4) 15 (3) 
   Remote (RA4) 2 (0.6) 0 (0) 2 (0.4) 
Non-adherence 35 (10) 10/144 45/484 
   Declined ICD‡ 12 (10) - 12 (10) 
   Cardiology review 13 (4) - 13 (4) 
   Competitive sports 2 (0.6) - 2 (0.6) 
   Decline medication 8 (2) - 8 (2) 
   Clinical screening - 10/144 - 
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FIGURE LEGENDS 
 
FIGURE 1: Participant recruitment to the study 
The consecutive clinic group included those seen between 2011-2013.  A broader group of 
participants from the specialized cardiac genetic clinic (2002-2013) and Australian Genetic 
Heart Disease Registry were invited to complete the survey. 
 
FIGURE 2: Flowchart of the specialized cardiac genetic clinic 
The specialized cardiac genetic clinic incorporates cardiology opinion and management, 
clinical surveillance of relatives, genetic counseling and testing options and education.  
 
FIGURE 3: Distribution of (A) Index of Socioeconomic Advantage and Disadvantage 
(IRSAD), (B) Index of Education and Occupation (IEO) and (C) Geographic 
remoteness areas, for consecutive patients attending a specialized clinic 
The majority of patients seen during the study time period resided in (A) socioeconomically 
advantaged (B) highly educated and (C) major metropolitan areas.   
Abbreviations: RA1, major cities of Australia; RA2, inner regional; RA3, outer regional; 
RA4, remote; and RA5, extremely remote.  
 
FIGURE 4: Spider-plots of the SF-36v2 domain scores by (A) Education level, (B) 
Household income and (C) Geographic remoteness amongst patients with 
hypertrophic cardiomyopathy 
Health-related quality of life (HR-QoL) was impaired across a number of domains for 
patients with lower education level, lower household income and who were more 
geographically remote.  
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Abbreviations: PF, physical function; RP, role – physical; BP, bodily pain; GH, general 
health; VT, vitality; SF, social functioning; RE, role – emotional; MH, mental health; SES, 
socioeconomic status; RA1, metropolitan cities of Australia; RA2/RA3, inner and outer 
regional areas.  
*Indicates a significant difference 
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FIGURE 1: Flowchart of the specialized cardiac genetic clinic 
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FIGURE 2: Participant recruitment to the study 
 
 
Australian Genetic Heart Disease Registry  
(NSW site or not linked to any recruiting 
sites, i.e. self enrolment) 
HCM and Genetic Heart Disease clinics, 
Sydney (2002-2013) 
(2) Survey group: 
All HCM and at-risk relatives 
Aged 18 years and over 
Sufficient English skills 
N=275 
(1) Clinic group: 
All consecutive patients 
seen 2011-2013 
N=486 
! 27 
FIGURE 3: Distribution of socioeconomic indexes and geographic remoteness of consecutive patients attending a specialized 
clinic 
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FIGURE 4: Spider-plots of the SF-36v2 domain scores by (A) Education level (B) Household income and (C) Geographic 
remoteness amongst patients with hypertrophic cardiomyopathy 
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